Category: Specific Treatments

Specific Treatments

5-ASA

Mesalamine

Steroids

Budesonide

Infliximab

Remicade

Adalimumab

Humira

Thiopurines

Imuran, 6-MP

Vedolizumab

Entyvio

Ustekinumab

Stelara

Tofacitinib

Xeljanz

Email Newsletter

Recent News

IBD risk increases among first-degree relatives
October 7, 2020
Patient-favored discontinuation improved with Entyvio, Stelara in IBD
September 30, 2020
Small intestine cells at risk for COVID-19 infection in IBD patients
September 25, 2020
Pregnancy and IBD: Biologic risks similar to general population
September 25, 2020
Stelara shows favorable safety profile through 1-year of IBD treatment
September 23, 2020
Anti-TNF, thiopurine combination increase lymphoma risk in IBD
August 26, 2020
Number of antibiotic dispensations potentially linked with IBD development
August 25, 2020
Patients with IBD discontinue methotrexate at higher rate than thiopurines
August 18, 2020
FMT safe, well tolerated for recurrent CDI in IBD
July 31, 2020
Atopic disease linked with increased risk for IBD
July 30, 2020